BackImmunoCellular Therapeutics, Overview

ImmunoCellular Therapeutics, Goodwill

ImmunoCellular Therapeutics,'s goodwill is $0.

Get informed when a big investor buys or sells

+ Follow
Goodwill
$0.00

Peer trimmed avg / median

Loading

ImmunoCellular Therapeutics, Goodwill History

Loading

ImmunoCellular Therapeutics, vs. peers: Goodwill Comparison

Loading

ImmunoCellular Therapeutics, Goodwill Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ImmunoCellular Therapeutics, (IMUC) FAQ

As of the most recent data (September 2023), IMUC shows a goodwill of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IMUC's goodwill is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether ImmunoCellular Therapeutics, is outperforming or lagging.

Tracking IMUC's goodwill over time shows whether ImmunoCellular Therapeutics, is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this goodwill page, Stockcircle has ImmunoCellular Therapeutics,'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect goodwill (currently $0) with ownership activity and broader fundamentals.

ImmunoCellular Therapeutics,'s goodwill is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.